Pediatric Brain Tumor Populations Too Small For Non-Inferiority Trials – Cmte
Executive Summary
The heterogeneity of pediatric brain tumors generally precludes the use of non-inferiority trials to support approval, FDA's Pediatric Oncology Subcommittee determined